These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 8837309)

  • 1. Pharmacology of a new low molecular weight dermatan sulphate (Desmin) in healthy volunteers: repeated daily intramuscular administration of 400 mg for a week.
    Dettori AG; Zamboni V; Manotti C; Canova N; Barbanti M; Palazzini E
    Thromb Res; 1996 Jul; 83(1):103-9. PubMed ID: 8837309
    [No Abstract]   [Full Text] [Related]  

  • 2. Acute and chronic effects of a new low molecular weight dermatan sulphate (Desmin 370) on blood coagulation and fibrinolysis in healthy subjects.
    Legnani C; Palareti G; Biagi R; Ludovici S; Maggiore L; Milani MR; Coccheri S
    Eur J Clin Pharmacol; 1994; 47(3):247-52. PubMed ID: 7867677
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of low-molecular-weight dermatan sulfate on coagulation, fibrinolysis and tissue factor pathway inhibitor in healthy volunteers.
    Harenberg J; Jeschek M; Acker M; Malsch R; Huhle G; Heene DL
    Blood Coagul Fibrinolysis; 1996 Jan; 7(1):49-56. PubMed ID: 8845462
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A survey of the clinical experience with dermatan sulfate.
    Gianese F; Lucchelli PE
    Semin Thromb Hemost; 1991; 17 Suppl 2():199-204. PubMed ID: 1948090
    [No Abstract]   [Full Text] [Related]  

  • 5. Human pharmacokinetics and pharmacodynamics of MF 701 dermatan sulfate administered by continuous intravenous infusion.
    Agnelli G; Cosmi B; Renga C; Federici F; Nenci GG; Houin G; Gianese F
    Thromb Haemost; 1990 Oct; 64(2):256-9. PubMed ID: 2270533
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tolerability and clinical efficacy of desmin in the treatment of superficial thrombovaricophlebitis.
    Andreozzi GM; Signorelli S; Di Pino L; Martini R; Marchitelli E; Pinto A; Romeo S; Zamboni V; Palazzini E
    Angiology; 1996 Sep; 47(9):887-94. PubMed ID: 8810655
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antithrombotic activity of Desmin 370. Comparison with a high molecular weight dermatan sulfate.
    Barbanti M; Calanni F; Babbini M; Bergonzini G; Parma B; Marchi E; Wassermann A
    Thromb Res; 1993 Sep; 71(5):417-22. PubMed ID: 8236168
    [No Abstract]   [Full Text] [Related]  

  • 8. Bioavailability of Desmin, a low molecular weight dermatan sulfate, after subcutaneous administration to healthy volunteers.
    Miglioli M; Pironi L; Ruggeri E; Serra C; Zamboni V; Barbanti M; Canova N; Calanni F; Milani MR; Palazzini E
    Int J Clin Lab Res; 1997; 27(3):195-8. PubMed ID: 9352383
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacodynamic characteristics of low-molecular-weight dermatan sulphate after subcutaneous administration in acute myocardial infarction.
    Traini AM; Cervi V; Melandri G; Palazzini E; Zamboni V; Semprini F; Candiotti N; Branzi A
    J Int Med Res; 1994; 22(6):323-31. PubMed ID: 7895895
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacodynamic study of low molecular weight dermatan sulphate (Desmin) after a single subcutaneous administration in patients with renal insufficiency.
    Saivin S; Boneu B; Ducret F; Pourrat J; Palazzini E; Zamboni W; Duchêne P; Houin G
    Arzneimittelforschung; 2000 Sep; 50(9):821-6. PubMed ID: 11050699
    [TBL] [Abstract][Full Text] [Related]  

  • 11. On the action of a heparan-like glycosaminoglycan (Hemovasal) on the mechanism of haemostasis and fibrinolysis.
    Zawilska K; Elikowski W; Turowiecka Z; Zozulinska M; Grzywacz A; Przybyl L; Vinazzer H
    Thromb Res; 1995 May; 78(3):211-6. PubMed ID: 7631301
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of subcutaneously administered dermatan sulfate (MF 701) on the coagulation and fibrinolytic parameters of healthy volunteers.
    Tripodi A; Moia M; Bottasso B; Tenconi PM; Gianese F; Mannucci PM
    Thromb Res; 1991 Jun; 62(6):663-72. PubMed ID: 1926059
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacological actions of sulodexide.
    Ofosu FA
    Semin Thromb Hemost; 1998; 24(2):127-38. PubMed ID: 9579633
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacology of desmin (low molecular weight dermatan sulphate) in healthy volunteers following intravenous bolus administration of different dosages (200, 400, 800 mg).
    Dettori AG; Milani MR; Manotti C; Zamboni V; Palazzini E; Barbanti M
    Thromb Res; 1995 Aug; 79(3):249-60. PubMed ID: 8533121
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anticoagulant and antithrombin effects of intimatan, a heparin cofactor II agonist.
    Buchanan MR; Brister SJ
    Thromb Res; 2000 Sep; 99(6):603-12. PubMed ID: 10974347
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics of Clivarin a new low molecular weight heparin in healthy volunteers.
    Andrassy K; Eschenfelder V; Koderisch J; Weber E
    Thromb Res; 1994 Jan; 73(2):95-108. PubMed ID: 7802862
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dermatan sulphate for the prevention of postoperative venous thromboembolism in patients with cancer. DOS (Dermatan sulphate in Oncologic Surgery) Study Group.
    Di Carlo V; Agnelli G; Prandoni P; Coccheri S; Gensini GF; Gianese F; Mannucci PM
    Thromb Haemost; 1999 Jul; 82(1):30-4. PubMed ID: 10456450
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A chronopharmacodynamic study on standard heparin, a low molecular weight heparin (nadroparin) and danaproid: establishing and comparing the daily variations of these drugs in rats.
    Abrial D; Blanc A; Réhailia M; Mismetti P; Bouchut C; Laporte-Simitsidis S; Decousus H; Buisson B
    Haemostasis; 2000; 30(5):233-42. PubMed ID: 11251330
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antithrombotic and anticomplementary properties of a very low molecular mass dermatan sulfate.
    Fabiana Alberto M; Giaquinta Romero D; Lazzari M; Calabrese GC
    Thromb Res; 2008; 122(1):109-16. PubMed ID: 17936880
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Low molecular weight heparin is responsible for the anti-Xa activity of Desmin 370.
    Brieger D; Dawes J
    Thromb Haemost; 1996 Feb; 75(2):286-91. PubMed ID: 8815578
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.